Researchers Identified Propionyl-CoA Signaling in Prostate Cancer
A newly discovered metabolic pathway may explain how prostate cancer cells drive tumor aggressiveness.
Updated on Oct. 9, 2026 in Cancer
Scientists have determined that the molecule propionyl-CoA plays a critical role in promoting the growth of metastatic prostate tumors. The research reveals that this metabolite acts as a donor for modifying a specific protein, which subsequently accelerates cholesterol production and cancer progression.
Why it matters
Understanding this signaling mechanism opens potential new avenues for treatment by targeting how tumor cells produce and utilize energy. By blocking the synthesis of propionyl-CoA, researchers found they could make cancer cells more sensitive to existing androgen deprivation therapies.
The study identified that metastatic prostate tumors exhibit lower levels of propionyl-CoA catabolism enzymes compared to hormone-sensitive primary tumors. This metabolic shift increases the availability of propionyl-CoA, which stabilizes the transcription factor SREBP2.
The players
SREBP2
This transcription factor regulates cholesterol synthesis and is stabilized by propionylation in the context of prostate cancer.
The details
Propionyl-CoA facilitates the lysine propionylation of the transcription factor SREBP2, a process that boosts cholesterol synthesis and androgen receptor signaling. This metabolic chain reaction leads to increased lipid accumulation, which directly fuels the aggressiveness of the tumors.
Timeline
The study was published on October 9, 2026.
The Big Picture
This research builds upon the historical reliance on androgen deprivation therapy for prostate cancer treatment by identifying a molecular mechanism to enhance its effectiveness. The discovery highlights how specific metabolic pathways can be exploited to overcome tumor resistance.
This research could eventually lead to new therapeutic strategies that combine metabolic inhibitors with traditional hormone treatments. Patients may benefit from more personalized approaches that target the specific metabolic drivers of their cancer cells.
The takeaway
This discovery highlights the complex link between tumor metabolism and cancer aggression. Future treatments targeting the production of propionyl-CoA could offer a vital way to improve outcomes for patients with metastatic prostate cancer.
Further reading
Learn more about the latest research in the field of Cancer.
Source note: This article includes information reported by Nature.
